Back to search results

Understanding the Impact of COVID-19 on Pulmonary Procedures

This study is looking at how pulmonary medicine programs in the United States changed their practices during the COVID-19 pandemic. Researchers want to understand how these programs adapted their procedures, staffing, and techniques. The goal is to learn from these experiences to help guide future pulmonary programs and improve how they respond to pandemics. This study is for pulmonologists (doctors who specialize in lung conditions) who are members of the American Association of Bronchology and Interventional Pulmonology (AABIP) or the American College of Chest Physicians (ACCP). Participants will complete a survey. This study is observational, meaning it gathers information without giving any specific treatments. There are no biomarkers or mechanisms being detected in this study.

Study design
This is an observational study aiming to enroll 250 participants. It involves gathering information through a survey.
What's involved
Participants will complete a survey that takes 5-10 minutes.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05022446

The Impact of COVID-19 on Pulmonary Procedures

Recruiting
Not specifiedAll AgesObservational
M.D. Anderson Cancer Center
~250 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:Survey Administration

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
To evaluate the pulmonary medicine programs adapted that their procedural practices in response to the coronavirus-2019 (COVID-19) epidemic.
Measured over through study completion, an average of 1 year
+3 more outcomes measured

Conditions

COVID-19 Infection
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm

Explore related trials

COVID-19 InfectionHematologic NeoplasmSolid Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Bruce F Sabath, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Jhankruti F Zaveri, MPH
[email protected]
(713) 745-2645
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Pulmonologists that are members of the American Association of Bronchology and Interventional Pulmonology (AABIP) and/or the American College of Chest Physicians (ACCP)
These organizations were chosen because their member databases are composed of pulmonologists in the United States (U.S.) that perform the pulmonary procedures described in this survey. Letters of approval will be obtained from these organizations and provided to the MD Anderson Institutional Review Board (IRB). Once the MD Anderson IRB approves this survey study, the survey will be sent to the relevant subcommittees of these organizations for their electronic dissemination to their membership

What this trial measures

  • To evaluate the pulmonary medicine programs adapted that their procedural practices in response to the coronavirus-2019 (COVID-19) epidemic.through study completion, an average of 1 year
  • To evaluate the pulmonary medicine programs that adapted their provider staffing in response to the coronavirus-2019 (COVID-19) epidemic.through study completion, an average of 1 year
  • To evaluate the pulmonary medicine programs that adapted their techniques in response to the coronavirus-2019 (COVID-19) epidemic.through study completion, an average of 1 year
  • To evaluate the pulmonary medicine programs that adapted their ambulatory operations in response to the coronavirus-2019 (COVID-19) epidemic.through study completion, an average of 1 year